Medtech company Beta Bionics targets USD$616 million IPO valuation

California-based insulin delivery device manufacturer Beta Bionics have stated their intentions to target an IPO valuation of USD$616 million in the United States, signalling an optimistic recovery of medtech and biotech public listings.

Demand for pharmaceutical and drug delivery innovation exploded during the COVID-19 pandemic years. However, as the world emerged from the pandemic throughout 2023 and beyond, the pharmaceutical industry witnessed some of the lowest indices by October 2023 as demand slowed. As 2024 progressed, IPO activity in the medtech sector showed steady recoveries despite high interest rates in recent years, demonstrating renewed interest in innovative healthcare solutions post-pandemic. For example, medical device maker launched in 2024 with USD$180 million raised in its upsized IPO, with shares up 35% from offer price as of last close.

Seeking to raise up to USD$120 million, Beta Bionics is offering 7.5 million shares at prices ranging from USD$14-$16 each. Based in Irvine, California, net sales for the company climbed to USD$44.7 million in 2024 over 9 months as compared to the USD$3.6 million raised the year before. This followed the US FDA’s approval and commercialisation of their insulin delivery system iLet in May 2023. However, Beta Bionics also listed a net loss of USD$36.6 million, compared with USD$25.3 million the year before.

Current investors in Beta Bionics include healthcare investment first Soleus Capital and RTW Investments. Asset management firm Wellington Management has agreed to purchase USD$17 million in Beta Bionics shares, in a concurrent private placement at IPO prices. Underwriters for the offering include BofA Securities, Piper Sandler, Leerink Partners, Stifel, and Lake Street.

Source:

1. Beta Bionics targets up to $616 mln valuation in US IPO [Accessed January 23, 2025] https://www.reuters.com/business/healthcare-pharmaceuticals/beta-bionics-targets-up-616-mln-valuation-us-ipo-2025-01-22/

2. 2025 Pharma Trends Outlook: Collaborative Pharma – A New Era of Supply Chains [Accessed January 23, 2025] https://www.cphi-online.com/2025-pharma-trends-outlook-collaborative-pharma-a-news126204.html